source
- Teva reports positive mid-stage results for celiac disease antibody, BioMarin settles patent fight with AscendisTeva said its experimental antibody TEV-408 showed statistically significant and clinically meaningful reduction in gluten-induced intestinal damage in a mid-stage trial for celiac disease. The tr…
- Novartis to cut about 130 jobs in Switzerland as it reshapes biologics production in BaselNovartis announced it will eliminate roughly 130 positions in Switzerland as part of a reorganization of its biologics technical development and manufacturing footprint in Basel. The company plans…